The PhosphoPlus® MEK1/2 (Ser217/221) Antibody Kit provides reagents and protocols for the rapid analysis of the phosphorylation status of MEK1/2 at Ser217/221.
Phospho-MEK1/2 (Ser217/221) Antibody detects endogenous levels of MEK1/2 only when phosphorylated at serines 217 and 221. It will also react with MEK1/2 singly phosphorylated at Ser217 and singly phosphorylated at Ser221. MEK1/2 (D1A5) Rabbit mAb recognizes endogenous levels of total MEK1 and MEK2 proteins.
Monoclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues around Ser217/221 of human MEK1/2 and synthetic peptide corresponding to residues surrounding Ala220 of human MEK1 protein.
MEK1 and MEK2, also called MAPK or Erk kinases, are dual-specificity protein kinases that function in a mitogen activated protein kinase cascade controlling cell growth and differentiation (1-3). Activation of MEK1 and MEK2 occurs through phosphorylation of two serine residues at positions 217 and 221, located in the activation loop of subdomain VIII, by Raf-like molecules. MEK1/2 is activated by a wide variety of growth factors and cytokines and also by membrane depolarization and calcium influx (1-4). Constitutively active forms of MEK1/2 are sufficient for the transformation of NIH/3T3 cells or the differentiation of PC-12 cells (4). MEK activates p44 and p42 MAP kinase by phosphorylating both threonine and tyrosine residues at sites located within the activation loop of kinase subdomain VIII.
Explore pathways + proteins related to this product.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
PhosphoPlus is a trademark of Cell Signaling Technology, Inc.
LumiGLO is a registered trademark of Kirkegaard & Perry Laboratories.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.